Atlas Trials

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Clinical trial NCT05443646 · UNKNOWN

Trial details

NCT number
NCT05443646
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Limited Stage Small Cell Lung Cancer
Start date
2022-09-23
Primary completion
2024-06-30
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.